{"filing":{"accession_number":"0001104659-26-090056","cik":"0001561921","ticker":"TELA","company_name":"TELA Bio, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-03","primary_document":"tm2622121d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926090056/tm2622121d1_8k.htm"},"events":[{"id":23819,"run_id":21544,"accession_number":"0001104659-26-090056","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The filing discloses the appointment of Heather Getz as Chief Executive Officer and Class II director of TELA Bio, effective August 3, 2026. While the section also covers the concurrent departure of Antony Koblish as CEO and director, the substantive focus and forward-looking impact center on Ms. Getz's appointment, her extensive healthcare/medical device executive background, and the detailed terms of her employment agreement including base salary ($650,000), bonus structure, severance provisions, and substantial equity grants (2.87 million shares in options and RSUs). This is a material C-suite leadership transition that would affect investor assessment of the company's strategic direction and governance.","company_name":"TELA Bio, Inc.","ticker":"TELA","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24156,"accession_number":"0001104659-26-090056","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Heather Getz as Chief Executive Officer and Class II director of TELA Bio, effective August 3, 2026. While the section also covers the concurrent departure of Antony Koblish as CEO and director, the substantive focus and forward-looking impact center on Ms. Getz's appointment, her extensive healthcare/medical device executive background, and the detailed terms of her employment agreement including base salary ($650,000), bonus structure, severance provisions, and substantial equity grants (2.87 million shares in options and RSUs). This is a material C-suite leadership transition that would affect investor assessment of the company's strategic direction and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:19:47.837964+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24156,"accession_number":"0001104659-26-090056","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Heather Getz as Chief Executive Officer and Class II director of TELA Bio, effective August 3, 2026. While the section also covers the concurrent departure of Antony Koblish as CEO and director, the substantive focus and forward-looking impact center on Ms. Getz's appointment, her extensive healthcare/medical device executive background, and the detailed terms of her employment agreement including base salary ($650,000), bonus structure, severance provisions, and substantial equity grants (2.87 million shares in options and RSUs). This is a material C-suite leadership transition that would affect investor assessment of the company's strategic direction and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:19:47.837964+00:00","company_name":"TELA Bio, Inc.","ticker":"TELA","filing_date":"2026-08-04"}]}